Epigenomics AG
Epigenomics AG (ECX.DE) Stock Competitors & Peer Comparison
See (ECX.DE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ECX.DE | €0.70 | -11.17% | 612.6K | -0.04 | -€19.55 | N/A |
| TN8.DE | €448.70 | +1.01% | 166.7B | 29.56 | €15.18 | +0.33% |
| DAP.DE | €166.10 | +0.67% | 117.5B | 38.99 | €4.26 | +0.70% |
| ILU.DE | €112.64 | +1.06% | 17.2B | 24.28 | €4.64 | N/A |
| QIA.DE | €35.35 | +1.00% | 7.3B | 20.20 | €1.75 | +6.44% |
| SYAB.DE | €11.06 | -0.18% | 2.4B | 27.65 | €0.40 | N/A |
| NN6.DE | €1.49 | +1.36% | 18.7M | -10.61 | -€0.14 | N/A |
| ECX.F | €0.92 | -1.08% | 806.8K | -0.29 | -€3.15 | N/A |
| 4NC.F | €0.00 | +0.00% | 0 | 0.07 | €0.05 | N/A |
Stock Comparison
ECX.DE vs TN8.DE Comparison April 2026
ECX.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECX.DE stands at 612.6K. In comparison, TN8.DE has a market cap of 166.7B. Regarding current trading prices, ECX.DE is priced at €0.70, while TN8.DE trades at €448.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECX.DE currently has a P/E ratio of -0.04, whereas TN8.DE's P/E ratio is 29.56. In terms of profitability, ECX.DE's ROE is -0.74%, compared to TN8.DE's ROE of +0.13%. Regarding short-term risk, ECX.DE is more volatile compared to TN8.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ECX.DE.Check TN8.DE's competition here